iStock
The Scientist Speaks

Organoids in Space: The Next Frontier

Researchers take brain training to the next level by launching mini brains into outer space.

Share

Building miniature brains may sound like a page out of a science fiction novel, but fact is indeed stranger than fiction. Researchers around the world grow brain organoids—3D miniature brains—to better understand brain development, aging, injury, and other disorders, as well as to test new treatment strategies. Some scientists take brain building to the next level by launching their brain organoids into outer space. In this episode, Iris Kulbatski from The Scientist spoke with Alysson Muotri, a University of California, San Diego professor and Stem Cell Program director to learn more about how microgravity affects the cellular and molecular biology of brain organoids and how these discoveries can improve human health. 

More on this topic 

Science Philosophy in a Flash - A Rising Star Launches Brain Power into Outer Space

Time Traveling Mini-Brains on a Mission to Conquer Space

The Scientist Speaks is a podcast produced by The Scientist’s Creative Services Team. Our podcast is by scientists and for scientists. Once a month, we bring you the stories behind news-worthy molecular biology research. This month’s episode is sponsored by ACROBiosystems and Molecular Devices.


Speaker:

<strong >Alysson R. Muotri</strong>

Alysson R. Muotri, Ph.D.
Professor
Director of the Stem Cell Program
Institute for Genomic Medicine
University of California, San Diego                                                                                                                                              



ACROBiosystems is a cornerstone enterprise of the pharmaceutical and biotechnology industries. Our mission is to help overcome challenges with innovative tools and solutions from discovery to the clinic. We deliver solutions, whether they come through recombinant proteins, antibodies, assay kits, GMP-grade reagents, as well as organoids, to be used in discovery research and scalable to the clinical phase and beyond.

Molecular Devices is one of the world’s leading providers of high-performance bioanalytical measurement systems, software, and consumables for life science research, and pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for AI-driven automated cell culture workflows, high-throughput screening, genomic and cellular analysis, colony selection, and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics.

Top Image Credit:

iStock

Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Logo

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas